Market Activity, Upcoming Conference, Dividend, and New Agreement - Research Reports on Express Scripts, Boston Scientific, Zimmer, Medivation and Aetna

NEW YORK, September 12, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Express Scripts Holding Company (NASDAQ: ESRX), Boston Scientific Corporation (NYSE: BSX), Zimmer Holdings, Inc. (NYSE: ZMH), Medivation Inc. (NASDAQ: MDVN) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6428-100free.

--
Express Scripts Holding Company Research Reports
On September 9, 2014, shares in Express Scripts Holding Company (Express Scripts) declined 0.23% to end the trading session at $74.65, following Nasdaq Composite that lost 0.87% over the same trading session. Express Scripts' stock opened the session at $74.90 and fluctuated between $74.47 and $75.00, with 3.59 million shares changing hands. The stock has a 52-week high of $79.37 and a 52-week low of $59.20. Over the past one month, the stock has strengthened 4.55%, in line with the Nasdaq Composite that gained 4.15% over the same period of time. The Company's stock closed above its 50-day and 200-day moving averages of $70.64 and $71.47, respectively. The full research reports on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/Sep-12-2014/ESRX/report.pdf

--
Boston Scientific Corporation Research Reports
On September 3, 2014, Boston Scientific Corporation (Boston Scientific) announced that the Company will participate in the upcoming 2014 Bank of America Merrill Lynch Global Healthcare Conference on September 17, 2014 in London, England. In addition, the Company's Senior Vice President and President, Europe, Michael Onuscheck and Vice President, Investor Relations, Susan Lisa, will participate in a 40-minute question and answer session regarding the Company starting at approximately 10:40 a.m. GMT. The full research reports on Boston Scientific are available to download free of charge at:

http://www.analystsreview.com/Sep-12-2014/BSX/report.pdf

--
Zimmer Holdings, Inc. Research Reports
On August 26, 2014, Zimmer Holdings, Inc. (Zimmer) announced that the Company's Board of Directors has approved the payment of Q3 2014 cash dividend of $0.22 per share on its common stock. The Company informed that the dividend will be paid on or about October 31, 2014, to stockholders of record as of the close of business on September 26, 2014. The full research reports on Zimmer are available to download free of charge at:

http://www.analystsreview.com/Sep-12-2014/ZMH/report.pdf

--
Medivation Inc. Research Reports
On September 9, 2014, Medivation Inc.'s (Medivation) stock gained 2.01% to close the trading session at $94.34, creating a new 52-week high of $95.29. Shares in Medivation oscillated in the range of $92.06 - $95.29, after opening at $94.92. A total of 2.20 million shares were traded during the session, higher than its 30-day average volume of 1.00 million shares. In its latest quarterly results released on August 7, 2014, Medivation reported Q2 2014 collaboration revenues of $148.1 million, up 111.1% YoY and net income of $47.9 million (Q2 2013 net loss: $4.9 million). Since the release of Q2 2014 earnings, the Company's stock has surged 25.34%. The full research reports on Medivation are available to download free of charge at:

http://www.analystsreview.com/Sep-12-2014/MDVN/report.pdf

--
Aetna Inc. Research Reports
On September 9, 2014, Aetna Inc. (Aetna) announced that the Company has entered into new accountable care agreement with Weill Cornell Physicians, Cornell University's physician group, in order to improve care for approximately 9,000 of Aetna's commercial and Medicare members in New York. According to the new agreement for commercial members, Aetna will recognize the Weill Cornell Physicians Organization for achieving quality and efficiency benchmarks. In addition, the Company will help Weill Cornell in expansion of its care-management program and addition of health information technology that will benefit Aetna members. According to the Medicare arrangement, the Company will use CMS quality and efficiency measures to track Weill Cornell Physicians' performance and improve utilization of medical services and communication among medical professionals. Terry Golash, M.D., Senior Medical Director, Aetna, New York, said, "Many Medicare members have complex healthcare needs that go undetected. When care providers and insurers work together in a Medicare collaboration model, information and resources can be shared to improve care and direct outreach." The full research reports on Aetna are available to download free of charge at:

http://www.analystsreview.com/Sep-12-2014/AET/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED